Media.Player

Enhancing Oncolytic Virus Expression to Safely Optimize Efficacy

Detailed Technology Description

None

*Abstract

BackgroundOncolytic viruses are capable of replication, are tumor selective and can lyse cancer cells. After infection of the cancer cells, oncolytic viruses replicate from within, hijacking the cellular machinery of the cancer cell to produce and subsequently release new viruses. The release of the new viruses results in lysis of the cancer cell and the new viruses are then free to infect other cancer cells. The cycle of infection-replicationrelease can be repeated many times, and the result is the killing of the tumor mass. Oncolytic viruses also can be designed to express different proteins to enhance their therapeutic effects.Clinical use of live replicating viruses is associated, though, with a unique set of safety issues. Experience has so far provided evidence of limited efficacy but a favorabletoxicity profile. However, significant obstacles need to be overcome in the design of effective oncolytic virus treatment schedules. Locally administered virus does not generally spread to other tumor sites, and systemically administered virus is highly susceptible to efficient immune and nonimmune mediated clearance mechanisms.TechnologyInvestigators have discovered that the combination of oncolytic virus and a specific chemokine ligand leads to the most effective oncolytic viral delivery, replication and spread inside of a tumor mass. The co-administration of this chemokine ligand resulted in a decrease in the clearance of the oncolytic virus from the cancer tissue and facilitated recruitment of tumor-associated macrophage and increased cytokine expression of (interleukin (IL)-10(hi)/ IL-12(low)) in the tumor microenvironment.Application1. Enhance existing vaccines to more effective therapeutic vaccines2. Minimize vaccine boosts3. Enhance safety and efficacy of all oncolytic viruses.Advantages1. Technology is beyond proof-of-concept stage, supported by laboratory results and early clinical results2. Low overall R&D and clinical trial costs to enhance oncolytic vaccines3. Can be applied to all oncolytic virus-based vaccinesStage of Development1. Phase I clinical trials2. Preclinical animal data and some human data is available.Provisional Patent Application Filed

*Principal Investigator

Name: David Bartlett, Dr

Department: Med-Surgery

Name: Pawel Kalinski, Assistant Professor of Surgery

Department: Med-Surgery

Name: Pragatheeshwar Thirunavukarasu

Department: Med-Surgery

Name: Stephen Thorne

Department: Med-Surgery

Country/Region

USA